DJIA 17,356.87 288.00 1.69%
NASDAQ 4,644.31 96.48 2.12%
S&P 500 2,012.89 40.15 2.04%
market minute promo

20.24 1.47 (7.83%)

Quote as of

Extended Hours: $20.24 $0.00 (0.01%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

OMED $20.24 7.83%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $18.85
Previous Close $18.77
Daily Range $18.74 - $20.30
52-Week Range $16.57 - $42.34
Market Cap $603.8M
P/E Ratio -33.52
Dividend (Yield) $0.00 (0.0%)
Volume 138,285
Average Daily Volume 140,174
Current FY EPS -$1.66





News & Commentary Rss Feed

3 Large Cap Biotech Stocks That Could Pay Dividends, But Won't

Gilead Sciences, Celgene, and Biogen all have rock-solid financials, but none are likely to pay a dividend anytime soon.

OncoMed Pharmaceuticals Becomes Oversold (OMED)

OncoMed Begins Patient Dosing In Phase 2 Clinical Trial Of Tarextumab In Small Cell Lung Cancer

OncoMed Pharma Offers Data from New Clinical, Biomarker Trial from Tarextumab, Demcizumab

Oncomed Offers Data from Phase 1a Trial of OMP-52M51 in Oral Plenary Session

5 Things Celgene Corporation's Management Wants You to Know

Following another strong quarterly earnings report, here are five things Celgene's management team would like investors to know.

Oncomed Pharmaceuticals' (OMED) CEO Paul Hastings on Q3 2014 Results - Earnings Call Transcript

Can Celgene Corporation Stock Motor to $150 Following Earnings?

After reporting another stellar quarter of estimate-topping profits, could this biotech behemoth gain another 50% and push its share price to $150 per share?

Is It Time To Consider OncoMed Pharmaceuticals Again?

OncoMed Pharmaceuticals (OMED) Jumps: Stock Up 5.4% - Tale of the Tape

See More OMED News...